BAM
GLMD icon

Belpointe Asset Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Belpointe Asset Management’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-78
Closed -$5.99K – 1653
2023
Q1 		$5.99K Hold
78
– – ﹤0.01% 2942
2022
Q4 		$7.03K Buy
+78
New +$5.11K ﹤0.01% 2796

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TFGT
TS Financial Group (TSFG) Lake Forest, Illinois $794M AUM 24.65% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BCM
Bourgeon Capital Management Darien, Connecticut $679M AUM 50.89% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Belpointe Asset Management's GLMD Position: Q2 2023 in Review

Belpointe Asset Management sold out of Galmed Pharmaceuticals (GLMD) in Q2 2023, closing a stake of 78 shares — an estimated $5.99K sold.

Belpointe Asset Management first reported a position in GLMD in Q4 2022 and held it in 2 quarters. The position peaked at $7.03K in Q4 2022. 11 funds tracked by Wall St. Rank hold GLMD as of Q2 2023.

  • Belpointe Asset Management reported no remaining Galmed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 78 Galmed Pharmaceuticals shares in Q2 2023, an estimated $5.99K.
  • Belpointe Asset Management first reported a position in Galmed Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Galmed Pharmaceuticals position peaked at $7.03K in Q4 2022.
  • 11 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.